3 completed, 2 not yet recruiting. 3 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Tocilizumab biosimilar: new trials by email Literature Review of Tocilizumab biosimilar trials Research Report on Tocilizumab biosimilar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) MK-6255, CD8 PET Tracer, Acetaminophen - Ovarian Neoplasms, Endometrial Neoplasms | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 80 | 2026-11-13 | 2026-10-13 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-09 | 2026-10-08 |
| A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers Complarate, Actemra® - Healthy Volunteers | Phase 1 | Completed | AO GENERIUM | 256 | 2024-06-20 | 2026-09-21 |
| Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis Complarate®, Actemra® - Rheumatoid Arthritis | Phase 3 | Completed | AO GENERIUM | 465 | 2023-02-13 | 2024-07-03 |
| A Safety and Pharmacokinetic Study of Complarate (Tocilizumab Biosimilar) and Actemra® in Healthy Volunteers Complarate®, Actemra® - Healthy Volunteers | Phase 1 | Completed | AO GENERIUM | 43 | 2022-04-11 | 2024-07-01 |
Arthritis, Rheumatoid (1) · Endometrial Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia, B-Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Ovarian Neoplasms (1)
AO GENERIUM (3) · Merck Sharp & Dohme LLC (2)
Russia (3) · Israel (1)
2025 (1)